Poster Session A

Poster Session A: Prostate Cancer
Trials in Progress Poster Session A: Prostate Cancer

Thursday, February 14: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

Localized Disease: Poster Boards A1, A3, A13-F13, N1-N3
Advanced Disease: Poster Boards A2, A4-A12, F14-M22, N4-P3

BOARD A1
Abstract 1: PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
First Author: Nicholas Van As, MBBCH, MRCP, FRCR, MD(res)


BOARD A2
Abstract 139: Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).
First Author: Silke Gillessen, MD


BOARD A3
Abstract 2: A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.
First Author: Scott Williams, MBBS, MD


BOARD A4
Abstract 140: ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Karim Fizazi, MD, PhD


BOARD A5
Abstract 141: Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).
First Author: Karim Fizazi, MD, PhD


BOARD A6
Abstract 142: Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
First Author: Padmanee Sharma, MD, PhD


BOARD A7
Abstract 143: Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.
First Author: Howard Scher, MD, FASCO


BOARD A8
Abstract 144: Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Eric Small, MD, FASCO


BOARD A9
Abstract 145: Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Evan Yu, MD


BOARD A10
Abstract 146: Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer.
First Author: William Chen, BS


BOARD A11
Abstract 147: Cost-effectiveness of metastasis-directed therapy in the setting of oligometastatic hormone-sensitive prostate cancer.
First Author: Neil Parikh, MD, MBA


BOARD A12
Abstract 148: A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
First Author: Orazio Caffo, MD


BOARD A13
Abstract 3: SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation.
First Author: Yasir Alayed, FRCPC, MD, MSc


BOARD A14
Abstract 4: Time to PSA nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy.
First Author: Luke Pike, MD, D.Phil


BOARD A15
Abstract 5: Rectal toxicity results for patients treated with HDR brachytherapy as monotherapy versus dose-escalated external beam radiotherapy for localized prostate cancer.
First Author: Jacob Parzen, MD


BOARD A16
Abstract 6: Using PSMA (prostate-specific membrane antigen) evaluation on prostate biopsies for risk stratification at time of initial diagnosis.
First Author: Marie Hupe, MD


BOARD A17
Abstract 7: Hypofractionated, accelerated radiotherapy to the prostate bed: Five-year outcomes of a prospective phase I/II study.
First Author: Kevin Martell, BSc, MD


BOARD A18
Abstract 8: A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy.
First Author: Stephen Freedland, MD


BOARD A19
Abstract 9: Small cell carcinoma of the prostate: National patterns of care and outcomes.
First Author: Zachary Horne


BOARD A20
Abstract 10: Active surveillance and watchful waiting for low-risk prostate cancer in black patients: A population-based analysis.
First Author: Santino Butler, BA


BOARD A21
Abstract 11: “Management Migration” in United States patients diagnosed with localized prostate cancer from 2010-2015.
First Author: Santino Butler, BA


BOARD A22
Abstract 12: Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
First Author: Amandeep Mahal, BS


BOARD B1
Abstract 13: Management of low-risk prostate cancer in a population-based cohort of Australian men between 2008 and 2016.
First Author: Wee Loon Ong, MBBS, MPhil


BOARD B2
Abstract 14: Validation of MSKCC pre-prostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy.
First Author: Zachary Glaser, MD


BOARD B3
Abstract 15: Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.
First Author: Jeremie Calais, MD


BOARD B4
Abstract 16: Second cancer following radical prostate cancer treatment.
First Author: Bjorg Aksnessaether, MD


BOARD B5
Abstract 17: Genomic validation of three-tiered sub-classification of high-risk prostate cancer.
First Author: Vinayak Muralidhar, MD, MSc


BOARD B6
Abstract 18: GATA2 exosomal mRNA: A novel urine biomarker for the diagnosis of clinically significant prostate cancer.
First Author: Jungreem Woo, PhD


BOARD B7
Abstract 19: Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance?
First Author: Marc Dall'era, MD


BOARD B8
Abstract 20: Outcomes of the patients with pT0 on first protocol biopsy during active surveillance for early prostate cancer: From the PRIAS-JAPAN study.
First Author: Takuma Kato, MD


BOARD B9
Abstract 21: External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.
First Author: Vinayak Muralidhar, MD, MSc


BOARD B10
Abstract 22: Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.
First Author: Scott Williams, MBBS, MD


BOARD B11
Abstract 23: SPINK1 expression and outcomes postprostatectomy in race-specific cohorts.
First Author: Farzana Faisal, MD


BOARD B12
Abstract 24: Percent genome alteration and outcomes after radical prostatectomy in African American men.
First Author: Farzana Faisal, MD


BOARD B13
Abstract 25: Safety of high dose rate prostate brachytherapy in patients with high baseline international prostate symptom scores.
First Author: Tiffany Morgan, MD


BOARD B14
Abstract 26: Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer.
First Author: Sunil Dutta, MD


BOARD B15
Abstract 27: Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study.
First Author: Darren Poon


BOARD B16
Abstract 28: The effect of the timing of biochemical failure after external beam radiotherapy or low-dose-rate brachytherapy for definitive prostate cancer treatment.
First Author: Jay Ciezki, MD


BOARD B17
Abstract 29: Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.
First Author: Andrew Armstrong, MD


BOARD B18
Abstract 30: SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer.
First Author: Gretchen Hoyer, None


BOARD B19
Abstract 31: Questioning the status quo: Should Gleason 3+3=6 PCa be considered a “negative core” for pre-RP risk nomograms?
First Author: Joon Yau Leong, BS


BOARD B20
Abstract 32: Incorporating mpMRI Biopsy data into established pre-RP nomograms: Potential impact of an increasingly common clinical scenario.
First Author: Joon Yau Leong, BS


BOARD C1
Abstract 33: Multi-institutional analysis of synchronous prostate and rectosigmoid cancers.
First Author: Corbin Jacobs, MD


BOARD C2
Abstract 34: The impact of intraductal carcinoma of the prostate on the grade group system.
First Author: Masashi Kato, MD, PhD


BOARD C3
Abstract 35: A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) ± degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03.
First Author: Simon Pacey, PhD, FRCP


BOARD C4
Abstract 36: Impact of compliance on outcomes for patients on active surveillance for prostate cancer.
First Author: Jay Detsky, FRCPC, MD, PhD


BOARD C5
Abstract 37: Reducing overuse of PSA screening in primary care practices.
First Author: Cara Litvin, MD, MS


BOARD C6
Abstract 38: Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of decipher and PAM50 TESTS among different age groups.
First Author: Hanan Goldberg, MD


BOARD C7
Abstract 39: Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: A pooled prospective evaluation of quality of life.
First Author: Zachary Seymour, MD


BOARD C8
Abstract 40: Impact of putative chemopreventative agents on prostate cancer diagnosis.
First Author: Hanan Goldberg, MD


BOARD C9
Abstract 41: Prostate cancer-related quality of life and risk for anxiety and depression.
First Author: Shauna McManus, BS


BOARD C10
Abstract 42: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
First Author: Felix Feng, MD


BOARD C11
Abstract 43: Validation and physiological association of changes in magnetic resonance imaging radiomic features in response to androgen deprivation therapy in patients with high-risk prostate cancer.
First Author: Hannah Tharmalingam


BOARD C12
Abstract 44: Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.
First Author: Amar Kishan, MD


BOARD C13
Abstract 45: Does tumor location affect prostate cancer prognosis?
First Author: Jun Akatsuka, PhD


BOARD C14
Abstract 46: The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.
First Author: Harry Brastianos, MD, PhD


BOARD C15
Abstract 47: MRI-guided prostate brachytherapy dose escalation to the dominant intraprostatic lesions: A retrospective analysis of urinary toxicity and biochemical response.
First Author: George Wakil, FRCPC, MDCM


BOARD C16
Abstract 48: The predictive value of DRE in the modern era of prostate cancer diagnostics.
First Author: Joel Andersson, MD


BOARD C18
Abstract 50: Pretrial outlining quality assurance in PIVOTALboost.
First Author: Elin Evans, FRCR, MBBS


BOARD C19
Abstract 51: Multi-institutional analysis of high-risk prostate cancer patients treated with stereotactic body radiotherapy.
First Author: Naomi Jiang, MD


BOARD C20
Abstract 52: Early predicting factor for biochemical failure for patients with intermediate and high-risk prostate cancer treated by definitive radiotherapy.
First Author: Hye Jin Kang, MD


BOARD C21
Abstract 53: Performance of a validated urine exosome gene expression test (EPI) in men within the USPSTF suggested age-group of 55 to 69 years at initial biopsy with a PSA 2-10 ng/mL.
First Author: Michael Donovan, MD, PhD


BOARD C22
Abstract 54: Genomic analysis and clinical outcomes of Primary Gleason Pattern 5 (PG5) prostate cancer (PCa) treated with radical prostatectomy (RP).
First Author: Pedro Isaacsson Velho, MD


BOARD D1
Abstract 55: Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.
First Author: Adam Weiner, MD


BOARD D2
Abstract 56: Molecular characterization of longitudinally tracked prostate cancer foci in men on active surveillance for low risk disease.
First Author: Jeffrey Tosoian, MD, MPH


BOARD D3
Abstract 57: Identification of differentially expressed genes to predict radioresistant prostate carcinomas.
First Author: Tim Nestler, MD


BOARD D4
Abstract 58: A multibiomarker approach to predict prostate cancer pathology outcomes.
First Author: Pamela Paris, PhD


BOARD D5
Abstract 59: Hypofractionated dose painting IMRT using 20 fractions for intermediate to high risk localised prostate cancer: Two-year outcome data (BIOPROP20, NCT02125175).
First Author: Isabel Syndikus


BOARD D6
Abstract 60: A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.
First Author: Noelia Sanmamed, MD


BOARD D7
Abstract 61: Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide.
First Author: Adam Sowalsky, PhD


BOARD D8
Abstract 62: Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.
First Author: Yuqian Yan, PhD


BOARD D9
Abstract 63: A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).
First Author: Fatima Karzai, MD


BOARD D10
Abstract 64: Predictors of prostate cancer-specific anxiety following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
First Author: Kamran Salari, B.S.


BOARD D11
Abstract 65: Cost implications of multi-parametric magnetic resonance imaging in prostate cancer active surveillance.
First Author: Michelle Yu, MD


BOARD D12
Abstract 66: Management of isolated local failures following stereotactic body radiation therapy for low to intermediate risk prostate cancer.
First Author: Nicolette Drescher


BOARD D13
Abstract 67: Ten year treatment complication outcomes of radical prostatectomy versus external beam radiation therapy versus brachytherapy for 1,503 patients with intermediate risk prostate cancer.
First Author: Barry Goy, MD


BOARD D14
Abstract 68: Is there a correlation between Gleason score and maximum standardized uptake value in locally advanced prostate cancer patients?
First Author: Onal Cem, Prof


BOARD D16
Abstract 70: Role of magnetic resonance imaging-transrectal ultrasound fusion targeted biopsy in the detection of prostate cancer in biopsy-naïve men: A literature based meta-analysis of randomized trials.
First Author: Xiang Tu


BOARD D17
Abstract 71: Correlation between PSA kinetics and detection rate of PSMA-PET in the setting of biochemical recurrent prostate cancer: A systematic review and meta-analysis.
First Author: Ricardo Pereira Mestre, MD


BOARD D18
Abstract 72: Racial disparities in survivorship care adherence among Medicare beneficiaries with prostate cancer.
First Author: Ravi Parikh, MD


BOARD D19
Abstract 73: Plasma citrulline levels as a biomarker for bowel toxicity in prostate stereotactic radiotherapy with or without pelvic nodal radiation.
First Author: Ciaran Fairmichael, MRCP


BOARD D20
Abstract 74: MiR-34a to enhance the radiosensitivity of 22RV1 and 22RV1-radiation resistance prostate cancer cell lines.
First Author: John Thoms, FRCPC


BOARD D21
Abstract 75: Cascade testing of men with prostate cancer in families with a spectrum of inherited cancers: Importance of attention to race.
First Author: Veda Giri, MD


BOARD D22
Abstract 76: Bowel and bladder reproducibility in image guided SBRT prostate: Results of a patterns of practice survey.
First Author: Jeremy Mandia, MD


BOARD E1
Abstract 77: Providers’ inability to estimate health literacy among African American (AA) patients (pts) with early prostate cancer (PCa).
First Author: William Martin-Doyle, MD, MPH


BOARD E2
Abstract 78: Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction).
First Author: Omar Mian, MD, PhD


BOARD E3
Abstract 79: Typical hormone deprivation side effects compared to SM-88 therapy for rising PSA.
First Author: Benjamin Gartrell, MD


BOARD E4
Abstract 80: Four-year outcomes of hypofractionated proton therapy for localized prostate cancer.
First Author: Amardeep Grewal, MD


BOARD E5
Abstract 81: The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer.
First Author: Bhandari Vinayak, BSc


BOARD E6
Abstract 82: Machine learning approaches to improve prostate cancer outcome.
First Author: Ronnie Rodrigues Pereira, BSc, MSc


BOARD E7
Abstract 83: Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.
First Author: Benjamin Gartrell, MD


BOARD E8
Abstract 84: Health literacy is a barrier to shared decision making in early prostate cancer (PCA) among African American (AA) men.
First Author: William Martin-Doyle, MD, MPH


BOARD E9
Abstract 85: Changing physician PSA screening behavior in men 70 years of age and older by use of the electronic medical record.
First Author: Joseph Presti, Jr., FACS, MD


BOARD E10
Abstract 86: Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).
First Author: Cecile Vicier, MD


BOARD E11
Abstract 87: Prospective evaluation of a new patient decision aid to enhance prostate cancer screening decision-making.
First Author: Michael Brooks, MD


BOARD E12
Abstract 88: Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.
First Author: Kyle Zuniga, BS


BOARD E13
Abstract 89: Outcomes of active surveillance for African-American men with prostate cancer: Results of a matched analysis.
First Author: Lewis Thomas, MD


BOARD E14
Abstract 90: Pilot study of dual imaging with 89Zr-IAB2M and 68Ga-PSMA-11 PET/CT prior to prostatectomy.
First Author: Muhammad Junaid Niaz, MBBS


BOARD E15
Abstract 91: Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer.
First Author: Tim Govers, PhD


BOARD E16
Abstract 92: Trends in complementary and alternative medicine use among newly diagnosed prostate cancer patients.
First Author: Kyle Zuniga, BS


BOARD E17
Abstract 93: Concordance of systematic and fusion biopsy with surgical pathology.
First Author: Alice Yu, MDCM


BOARD E18
Abstract 94: Clinical utility study of confirms mdx for prostate cancer in a community urology practice.
First Author: Paul Yonover, MD


BOARD E19
Abstract 95: Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian prostate cancer.
First Author: Janice Tan, MBChB, MRCP


BOARD E20
Abstract 96: Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.
First Author: Derya Tilki, MD


BOARD E21
Abstract 97: A 17-gene genomic prostate score as a predictor of adverse pathology for men on active surveillance.
First Author: Zachary Kornberg, BA


BOARD E22
Abstract 98: Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.
First Author: Jaime Herrera-Caceres, MD


BOARD F1
Abstract 99: Impact of testosterone replacement therapy after radiation therapy on prostate cancer outcomes.
First Author: Reith Sarkar, MS


BOARD F2
Abstract 100: Impact of testosterone replacement therapy after radical prostatectomy on prostate cancer outcomes.
First Author: Reith Sarkar, MS


BOARD F3
Abstract 101: Evaluation of preoperative prostate magnetic resonance imaging for cancer control and neurovascular tissue preservation during robotic radical prostatectomy.
First Author: Samuel Gold


BOARD F4
Abstract 102: Efficacy and toxicity from phase II study of dose escalation to intraprostatic tumor nodule in localized prostate cancer.
First Author: Julia Murray, FRCR, PhD


BOARD F5
Abstract 103: Risk factors for postprostate biopsy infection.
First Author: Jonathan Shoag, MD


BOARD F6
Abstract 104: One and done?: Utility of PSA density as a predictor of number of cores needed to detect clinically significant prostate cancer.
First Author: Graham Hale


BOARD F7
Abstract 105: Brachytherapy use for favorable-risk prostate cancer continues to decline in both academic and community centers despite superior survival compared to dose-escalated external beam radiation therapy.
First Author: Kevin Nguyen


BOARD F8
Abstract 106: External validation of prostatectomy incontinence nomogram (PIN).
First Author: Ruben Pinkhasov, MD, MPH


BOARD F9
Abstract 107: MRI-based prostate specific antigen density predicts Gleason score upgrade in an active surveillance cohort.
First Author: Samuel Washington, MD


BOARD F10
Abstract 108: MRI targeted biopsy dramatically increases detection of clinically significant prostate cancer while reducing the risk of indolent cancer detection.
First Author: Michael Ahdoot, MD


BOARD F11
Abstract 109: Optimizing the use of androgen deprivation therapy in men with localized intermediate risk prostate cancer in the era of modern dose-escalated radiation therapy.
First Author: Sagar Patel, MD


BOARD F12
Abstract 110: MRI-TRUS fusion-guided biopsy in obese patients: Does it reduce risk of prostate cancer upgrade on final pathology compared to systematic 12-core biopsy?
First Author: Samuel Gold


BOARD F13
Abstract 111: Incidence and pathological features of metachronous bladder cancer in prostate cancer patients treated with brachytherapy or radical prostatectomy in a single institution.
First Author: Kotaro Obayashi, MD


BOARD F14
Abstract 149: Late administration of luteinizing hormone-releasing hormone (LHRH) agonists and the impact on testosterone suppression in the real-world management of prostate cancer.
First Author: Przemyslaw Twardowski, MD


BOARD F15
Abstract 150: Efficacy of docetaxel and androgen receptor axis-targeted agents in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
First Author: Akiyuki Yamamoto, None


BOARD F16
Abstract 151: Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.
First Author: Adam Sharp, MD, MRCP, PhD


BOARD F17
Abstract 152: Targeting mediator subunits CDK8/CDK19 for treatment of advanced prostate cancer.
First Author: Marie Hupe, MD


BOARD F18
Abstract 153: Quality of life differences for LHRH-antagonist versus LHRH-agonist in special patient groups with cardiovascular comorbidities and higher tumor burden in patients with hormone-sensitive prostate cancer (hsPCa).
First Author: Jan Lehmann, MD


BOARD F19
Abstract 154: Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations.
First Author: Catherine Marshall, MD, MPH


BOARD F20
Abstract 155: Outcome, costs and dollar value of docetaxel and abiraterone in prostate cancer.
First Author: Helmy Guirgis, MD


BOARD F21
Abstract 156: Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography.
First Author: Christian Zurth, PhD


BOARD F22
Abstract 157: A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in metastatic castration-resistant prostate cancer.
First Author: Yu Jen Jan, MD


BOARD G1
Abstract 158: Low incidence of microsurges with biodegradable polymer-delivered, subcutaneously-administered leuprolide acetate in prostate cancer patients.
First Author: Eleni Efstathiou, MD, PhD


BOARD G2
Abstract 159: Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
First Author: Steven Yip, MD


BOARD G3
Abstract 160: A Genome-wide association study of metastatic prostate cancer.
First Author: Craig Teerlink, PhD


BOARD G4
Abstract 161: A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.
First Author: Fred Saad, MD, FRCS


BOARD G5
Abstract 687: Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
First Author: Andrew Armstrong, MD


BOARD G6
Abstract 163: Prostate cancer cost-of-care and evaluation of traditional cost control measures.
First Author: Dhruv Bansal, MBA, MD


BOARD G7
Abstract 164: A phase II, open-label, multi-arm study of TAS-115 for castration-resistant prostate cancer patients with bone metastases.
First Author: Hiroji Uemura, DrPH


BOARD G9
Abstract 166: Impact of the USPSTF recommendations on prostate cancer stage migration and de-novo metastatic prostate cancer.
First Author: Yu-Wei Chen, MD


BOARD G10
Abstract 167: The effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant, AR-variant prostate cancer (PCa) model 22Rv1.
First Author: Mark Markowski, MD, PhD


BOARD G11
Abstract 168: Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A multicenter randomized phase II trial (OCUU-CRPC study).
First Author: Taro Iguchi, MD, PhD


BOARD G12
Abstract 169: A phase I/II study of proxalutamide (GT0918), a potent androgen receptor blocker, in patients with mCRPC progressed after both hormonal therapy and chemotherapy.
First Author: Nicholas Vogelzang, MD, FASCO, FACP


BOARD G13
Abstract 170: Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christophe Massard, MD


BOARD G14
Abstract 171: Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Peter Fong, FRACP


BOARD G15
Abstract 172: Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Matthew Tucker, MD


BOARD G16
Abstract 173: A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Munjid Al Harthy, MD


BOARD G17
Abstract 174: Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.
First Author: Nicholas Vogelzang, MD, FASCO, FACP


BOARD G18
Abstract 175: Associations of cell cycle genetic variants with aggressive prostate cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
First Author: Melissa Huynh, MD


BOARD G19
Abstract 176: In geriatric evaluation, some iadl (Katz) scale items are more predictive of efficacy and toxicity than ADL (Lawton) scale or Charlson Comorbidity Index in metastasic castration-resistant protate cancer (mCRPC) patients treated with cabazitaxel in a weekly schedule.
First Author: Miguel Ángel Climent


BOARD G20
Abstract 177: Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew Armstrong, MD


BOARD G21
Abstract 178: Age-related variation in gene alteration frequency in metastatic prostate cancer.
First Author: Zachary Chalmers, BS


BOARD G22
Abstract 179: A noninvasive prognostic biomarker for metastatic castration-resistant prostate cancer: Very small nuclear circulating tumor cells.
First Author: Pin-Jung Chen, MD


BOARD H1
Abstract 180: A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223.
First Author: A. Sartor, MD


BOARD H2
Abstract 181: A genetic risk score to personalize prostate cancer screening, applied to population data.
First Author: Minh-Phuong Huynh-Le, MD


BOARD H3
Abstract 182: CCN3/NOV as a functional driver and prognostic biomarker of prostate cancer bone metastasis.
First Author: V?Ronique Ouellet


BOARD H4
Abstract 183: The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew Armstrong, MD


BOARD H5
Abstract 184: Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.
First Author: Krishna Bikkasani, BA


BOARD H6
Abstract 185: A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.
First Author: Ugo De Giorgi, MD, PhD


BOARD H7
Abstract 186: Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Susan Halabi, PhD, FASCO


BOARD H8
Abstract 187: Docetaxel in older patients for metastatic prostate cancer.
First Author: Frances Mark, MBChB, BSc, MRCP, FRCR


BOARD H9
Abstract 188: Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Kwan, MBBS, FRACP


BOARD H10
Abstract 189: Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.
First Author: Nicolas Delanoy, MD


BOARD H11
Abstract 190: Radium-223 treatment patterns in a large real-world population.
First Author: Hanson Zhao, MD


BOARD H12
Abstract 191: Determining androgen inactivation status in prostate cancer by [18F] DHT PET.
First Author: Ziqi Zhu, PhD


BOARD H13
Abstract 192: Outcomes of high-dose whole pelvic simultaneous integrated boost IMRT in patients with pelvic lymph node-positive prostate cancer.
First Author: Takashi Mizowaki, MD, PhD


BOARD H14
Abstract 193: The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.
First Author: Alexandra Sokolova, MD


BOARD H15
Abstract 194: Next Generation Sequencing (NGS) in metastatic castration resistant prostate cancer (mCRPC) to identify targets for individualized treatment: Is it feasible in daily routine?
First Author: Axel Heidenreich, MD


BOARD H16
Abstract 195: Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).
First Author: Simon Fu, FRACP


BOARD H17
Abstract 196: Toxicity results from a novel phase I/II trial of VMAT radiotherapy to prostate and pelvic nodes plus six cycles of radium-223 in mCSPC metastatic to bone post ADT and docetaxel.
First Author: Joe O'Sullivan, FRCR


BOARD H18
Abstract 197: Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jingsong Zhang, MD, PhD


BOARD H19
Abstract 198: Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastasic castration resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.
First Author: Miguel Ángel Climent


BOARD H20
Abstract 199: MiCheck performance: Comparator trial of MiCheck with PHI, % free PSA and PSA—The impact on decision making for prostate biopsy.
First Author: Neal Shore, FACS, MD


BOARD J1
Abstract 200: Genomic determinants of sensitivity to bipolar androgen therapy (BAT) in castrate-resistant prostate cancer (CRPC).
First Author: Michael Schweizer, MD


BOARD J2
Abstract 201: Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer.
First Author: Richard Gagnon, BSc, MD


BOARD J3
Abstract 202: Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.
First Author: Matthew Smith, MD, PhD


BOARD J4
Abstract 203: Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Vincenza Conteduca, M.D., Ph.D.


BOARD J5
Abstract 204: A multidisciplinary team-based approach to mitigate the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study.
First Author: YaoYao Pollock, MD


BOARD J6
Abstract 205: Prostate cancer-derived anti-GRP78 autoantibodies compromise the blood-brain barrier and accelerate atherosclerosis progression in vivo.
First Author: Ali Al-Hashimi, PhD


BOARD J7
Abstract 206: Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface GRP78.
First Author: Ali Al-Hashimi, PhD


BOARD J8
Abstract 207: ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.
First Author: Mercedes Marin


BOARD J9
Abstract 208: Association of serum androgen and drug levels with response to abiraterone.
First Author: Elahe Mostaghel, MD, PhD


BOARD J10
Abstract 209: The efficacy of enzalutamide for castration-resistant prostate cancer (CRPC) patients with intraductal carcinoma of the prostate (IDC-P).
First Author: Hideji Kawanishi, MD


BOARD J11
Abstract 210: Genomic characterization of pulmonary-metastatic prostate cancer: A unique molecular subtype.
First Author: Eugene Shenderov, MD, PhD


BOARD J12
Abstract 211: Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients.
First Author: Stephen Freedland, MD


BOARD J13
Abstract 212: Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
First Author: Megan McNamara, MD


BOARD J14
Abstract 213: Final analysis of a phase II study of MRI based functional imaging of bone metastases in men with metastatic castrate-resistant prostate cancer (mCRPC) receiving Cabozantinib.
First Author: Arpita Desai, MD


BOARD J15
Abstract 214: Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans.
First Author: Julio Chong, MD


BOARD J16
Abstract 215: An updated analysis evaluating skeletal related events (SREs) in CTRIAL-IE 13-21: Phase II trial of radium-223 (R223) in combination with enzalutamide (ENZA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: John Greene


BOARD J17
Abstract 216: Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.
First Author: Emmanuel Antonarakis, MD


BOARD J18
Abstract 217: Immunogenomic landscape of neuroendocrine small cell prostate cancer.
First Author: Lucia Nappi, MD, PhD


BOARD J19
Abstract 218: Circulating tumor (ct) DNA-based genomic profile of prostate cancer (PCa) patients with elevated carcinoembryonic antigen (CEA).
First Author: Pannaga Malalur, MD


BOARD J20
Abstract 219: Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.
First Author: Laura Marandino, MD


BOARD J21
Abstract 220: Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models.
First Author: Ronan Le Moigne, PhD


BOARD J22
Abstract 221: The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.
First Author: Vindhya Udhane, PhD


BOARD K1
Abstract 222: Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).
First Author: Kelvin Moses, MD, PhD


BOARD K2
Abstract 223: Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival—Real-world outcomes from a single UK centre.
First Author: Xue Yan Jiang, BSc, MSc, MBBS


BOARD K3
Abstract 224: Immunogenomic landscape of Neuroendocrine Prostate Cancer (NEPC).
First Author: Alison Ferguson, PhD


BOARD K4
Abstract 225: Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC.
First Author: Howard Scher, MD, FASCO


BOARD K5
Abstract 226: Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
First Author: Edwin Lin, MA


BOARD K6
Abstract 227: Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa).
First Author: Jose Mauricio Mota, MD, PhD


BOARD K7
Abstract 228: Results of a 50 patient single-centre phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
First Author: Michael Hofman, FRACP, MBBS


BOARD K8
Abstract 229: Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations.
First Author: Maria Carlo, MD


BOARD K9
Abstract 230: Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.
First Author: Kate Mahon, MBBS, FRACP, PhD


BOARD K10
Abstract 231: Predictors of positive lesions in 18F-fluciclovine PET/CT.
First Author: Helen Hougen, MD


BOARD K11
Abstract 232: Early 18F-FDHT PET/CT as a predictor of treatment response in mCRPC treated with enzalutamide.
First Author: Hilde Hoving, M.D.


BOARD K12
Abstract 233: Association between urinary, bowel, and hormonal treatment-related symptoms and clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC): PROSPER study.
First Author: Fred Saad, MD, FRCS


BOARD K13
Abstract 234: Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.
First Author: Noel Clarke


BOARD K14
Abstract 235: The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as a biomarker of taxane resistance in castration-resistant prostate cancer.
First Author: Oscar Reig


BOARD K15
Abstract 236: Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.
First Author: Benjamin Lowentritt, FACS, MD


BOARD K16
Abstract 237: Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.
First Author: Bertrand Tombal, MD, PhD


BOARD K17
Abstract 238: Cell plasticity associated to taxane-resistance in preclinical cell models and in circulating tumor cells from metastatic castration-resistant prostate cancer patients.
First Author: Ruth Montalbo, BSc


BOARD K18
Abstract 239: Risk of subsequent dementia from androgen deprivation therapy (ADT) versus orchiectomy among men with prostate cancer.
First Author: Ravi Parikh, MD


BOARD K19
Abstract 240: Methylation-associated miR193b silencing activates master drivers of aggressive prostate cancer.
First Author: Ying Mazzu, PhD


BOARD K20
Abstract 241: Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
First Author: Gang Chen, MD, PhD


BOARD K21
Abstract 242: Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer.
First Author: Manish Kohli, MD


BOARD K22
Abstract 243: The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.
First Author: Lauren Brady, BSc, PhD


BOARD L1
Abstract 244: Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
First Author: Cecile Vicier, MD


BOARD L2
Abstract 245: DNA repair germline pathogenic mutation associations with treatment duration and family history in prostate cancer.
First Author: James Vu


BOARD L3
Abstract 246: Modeling time from bone metastasis to death in a racially diverse cohort of military health care beneficiaries.
First Author: Jennifer Cullen, PhD


BOARD L4
Abstract 247: Aberrations in androgen receptor ctDNA varies by race in metastatic castrate-resistant prostate cancer.
First Author: Bryce Christensen, BS


BOARD L5
Abstract 248: Identification of bone involvement in patients with prostate cancer recurrence using 18F-fluciclovine PET/CT and impact on subsequent management.
First Author: Michael Kipper, MD


BOARD L6
Abstract 249: TP53 mutations in circulating tumor DNA in men with metastastic castration-resistant prostate cancer mCRPC.
First Author: Lynne Chapman, BS


BOARD L7
Abstract 250: Preliminary results of a two stage phase II study of 18F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.
First Author: Rachel Glicksman, BSc, MD, MSc


BOARD L8
Abstract 251: The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).
First Author: Kobe Chi Yung Yuen, PhD


BOARD L9
Abstract 252: Clinical characteristics of men with prostate cancer and evaluation of NCCN prostate cancer guidelines on germline genetic testing outcomes.
First Author: Samantha Greenberg, CGC, MPH, MS


BOARD L10
Abstract 253: Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel George, MD


BOARD L11
Abstract 254: Evaluation of circulating tumor DNA (ctDNA) with respect to germline alterations in metastatic castrate resistant prostate cancer patients.
First Author: Peter Steinwald


BOARD L12
Abstract 255: Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Marcus Moses


BOARD L13
Abstract 256: Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
First Author: Celestia Higano, MD, FACP


BOARD L14
Abstract 257: Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.
First Author: Ronan Le Moigne, PhD


BOARD L15
Abstract 258: Germline DNA repair mutations in men with prostate cancer are less frequent in African Americans as compared with Caucasians.
First Author: Piper Nicolosi, PhD


BOARD L16
Abstract 259: ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa, PhD


BOARD L17
Abstract 260: First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer.
First Author: Daksh Thaper, PhD


BOARD L18
Abstract 261: Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial.
First Author: Douglas Campbell, PhD


BOARD L19
Abstract 262: Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).
First Author: Daniel Lin, MD


BOARD L20
Abstract 263: Apalutamide (APA) or enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (CRPC): A systematic review and network meta-analysis of randomized clinical trials (RCTs).
First Author: Irbaz Bin Riaz, MBBS, MS


BOARD L21
Abstract 264: Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
First Author: Rebeca Lozano, MD


BOARD L22
Abstract 265: ctDNA and copy-number variant quantification in mCRPC at the time of progression.
First Author: Patrick Cotogno


BOARD M1
Abstract 266: Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy.
First Author: Panagiotis Vlachostergios, MD, PhD


BOARD M2
Abstract 267: Correlation between time to PSA progression (TTPP), radiographic progression-free survival (rPFS) and overall survival (OS) in first-line abiraterone/enzalutamide (Abi/Enza) and docetaxel (Doc) treated patients in a prospective cohort study.
First Author: David Lorente, MD


BOARD M3
Abstract 268: Racial disparities in radium-223 treatment in a large real-world population.
First Author: Hanson Zhao, MD


BOARD M4
Abstract 269: PARP-1 regulation of DNA repair factor availability.
First Author: Matthew Schiewer, PhD


BOARD M5
Abstract 270: Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive prostate cancer (mCSPC): A single institution experience.
First Author: Seanthel Delos Santos, None


BOARD M6
Abstract 271: Ductal and acinar carcinomas of the prostate: A comparative comprehensive genomic profiling study.
First Author: Nick Liu, MD


BOARD M7
Abstract 272: Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.
First Author: Vincenza Conteduca, M.D., Ph.D.


BOARD M8
Abstract 273: Sipuleucel-T to modify the B7-H3 immune checkpoint in men with castrate resistant prostate cancer.
First Author: Wei Phin Tan, MD


BOARD M9
Abstract 274: Treatment facility volume and survival in patients with advanced prostate cancer.
First Author: Shreyas Joshi, MD


BOARD M10
Abstract 275: EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC).
First Author: Sarmad Sadeghi, MD, PhD


BOARD M11
Abstract 276: Survival outcomes for adjuvant or salvage radiation in men with pN+M0 prostate cancer.
First Author: Jonathan Tward, MD, PhD


BOARD M12
Abstract 277: 3βHSD1 immunohistochemistry and HSD3B1 genotype in prostate cancer.
First Author: JJ Zhang, MD


BOARD M13
Abstract 278: Value of serum neuroendocrine markers in evaluation of neuroendocrine prostate cancer: A validation study using metastatic biopsies.
First Author: Panagiotis Vlachostergios, MD, PhD


BOARD M14
Abstract 279: Plasma-based exploratory biomarker analysis to evaluate GT0918 in a phase I/II study in mCRPC patients.
First Author: Jianjun Yu


BOARD M15
Abstract 280: Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.
First Author: Disharee Nath, B. Tech.


BOARD M16
Abstract 281: PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).
First Author: Michael Harrison, MD


BOARD M17
Abstract 282: Can we avoid radiotherapy with 18FCH PET/CT?
First Author: Julieta Iorio, CCRA


BOARD M18
Abstract 283: Somatic alterations in a seven-gene DDR gene panel predicts platinum sensitivity in advanced prostate cancer patients.
First Author: Panagiotis Vlachostergios, MD, PhD


BOARD M19
Abstract 284: Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy.
First Author: Alejandro Abello, MD


BOARD M20
Abstract 285: What is the clinical utility of next generation sequencing (NGS) in advanced urologic malignancies?
First Author: James Ryan Mark, MD


BOARD M21
Abstract 286: Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Sumanta Pal, MD


BOARD M22
Abstract 287: Obesity and metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials.
First Author: Alberto Martini, MD


BOARD N1
Abstract TPS136: Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
First Author: Jeremie Calais, MD


BOARD N2
Abstract TPS137: Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial.
First Author: Himanshu Nagar, MD


BOARD N3
Abstract TPS138: The “ProPSMA Study” clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy.
First Author: Michael Hofman, FRACP, MBBS


BOARD N4
Abstract TPS328: A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.
First Author: Simon Chowdhury, MD, PhD


BOARD N5
Abstract TPS329: A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8).
First Author: Matthew Dallos, MD


BOARD N6
Abstract TPS330: Design of phase Ib/II study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration- and androgen-blocking-agent-resistant prostate cancer.
First Author: Mark Markowski, MD, PhD


BOARD N7
Abstract TPS331: Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Blossom Mak, MBBS, FRACP


BOARD N8
Abstract TPS332: TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.
First Author: Michael Hofman, MBBS, FRACP


BOARD N9
Abstract TPS333: Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).
First Author: Ahmad Zarzour, MD


BOARD N10
Abstract TPS334: ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Geraldine Martineau


BOARD N11
Abstract TPS335: ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Mary-Ellen Taplin, MD


BOARD N12
Abstract TPS336: A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.
First Author: David Einstein, MD


BOARD N13
Abstract TPS337: TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal, MD


BOARD N14
Abstract TPS338: A phase II, dose finding, placebo-controlled, study of zuclomiphene citrate to amerliorate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer.
First Author: Robert Getzenberg, PhD


BOARD N15
Abstract TPS339: Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott Tagawa, MD, MS


BOARD N16
Abstract TPS340: PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Noel Clarke


BOARD N17
Abstract TPS341: A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).
First Author: David Einstein, MD


BOARD N18
Abstract TPS342: TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT).
First Author: Johann De Bono, FRCP, MB, MD, PhD


BOARD N19
Abstract TPS343: Genetic counseling processes and outcomes among prostate cancer patients (ProGen).
First Author: Donna Vatnick, BS


BOARD N21
Abstract TPS345: A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.
First Author: Carlo Buonerba


BOARD N22
Abstract TPS346: Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial.
First Author: Cameron Phillips, MD


BOARD P1
Abstract TPS347: A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
First Author: Vivek Narayan, MD, BA


BOARD P2
Abstract TPS348: A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
First Author: Michael Morris, MD


BOARD P3
Abstract TPS349: Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma.
First Author: Min Yuen Teo, MD, MRCP